Egaptivon pegol
- Generic Name
- Egaptivon pegol
- Drug Type
- Biotech
- CAS Number
- 934868-74-3
- Unique Ingredient Identifier
- DT0445S65M
Overview
Egaptivon pegol, formerly known as ARC1779, is a therapeutic aptamer antagonist of the A1 domain of von Willebrand Factor (vWF), the ligand for receptor glycoprotein 1b on platelets. Egaptivon pegol is being investigated for the treatment of thrombotic thrombocytopenic purpura and acute coronary syndromes. Egaptivon pegol is a therapeutic oligonucleotide ("aptamer") which blocks the binding of the A1 domain of vWF to the platelet GPIb receptor, thereby modulating platelet adhesion, activation, and aggregation under the high shear conditions of coronary arterial stenosis and plaque rupture.
Background
Egaptivon pegol, formerly known as ARC1779, is a therapeutic aptamer antagonist of the A1 domain of von Willebrand Factor (vWF), the ligand for receptor glycoprotein 1b on platelets. Egaptivon pegol is being investigated for the treatment of thrombotic thrombocytopenic purpura and acute coronary syndromes. Egaptivon pegol is a therapeutic oligonucleotide ("aptamer") which blocks the binding of the A1 domain of vWF to the platelet GPIb receptor, thereby modulating platelet adhesion, activation, and aggregation under the high shear conditions of coronary arterial stenosis and plaque rupture.
Indication
Platelet aggregation, thrombosis and acute coronary syndromes
Associated Conditions
No associated conditions information available.
Clinical Trials
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.